Where to inject peptides under the skin

Reviewed 12 sourcesPublished by PepVault

Where to inject subcutaneous peptides: belly, thigh or upper arm, how far from the navel, why rotating sites matters, and what is normal at the site after.

A woman sitting on the edge of her bed in the morning, her hand resting on her thigh
Last reviewed
Sources
12
Questions
9
Compounds
3

The short answer

Inject subcutaneous peptides into the fat just under the skin: the belly at least 5 cm (2 inches) from the navel, the front or outer thigh, or the back of the upper arm. Use a new spot each time, at least 2.5 cm (an inch) from the last, and skip skin that is bruised, scarred, tender or lumpy.

PepVault research · Last reviewed · 12 sources

Evidence: FDA labels for semaglutide and tirzepatide for the sites, absorption and site reactions; human insulin-injection studies and expert consensus for technique and rotation; one rat study for BPC-157. Site-specific data for peptides exist only for the approved GLP-1s.

Why does a peptide go into fat, not muscle?

In adults with diabetes, about 14 mm of fat sits under the skin of the belly, on average. That layer is where a subcutaneous peptide is meant to land. Ultrasound of 388 US adults with diabetes measured an average of 13.9 mm of fat on the belly, 10.4 mm on the thigh, 10.8 mm on the back of the arm and 15.4 mm on the buttocks, under skin only about 2 mm thick. Women carried about 5 mm more fat than men4.

The labels for semaglutide and tirzepatide say to inject under the skin and not into a muscle or a vein12. Muscle absorbs differently: in people who inject insulin, a shot that reaches muscle by mistake can be absorbed faster than intended3. From the fat, semaglutide reaches its peak in the blood 1 to 3 days after the injection2.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Where exactly on the body?

The labels for the approved GLP-1 peptides name three areas, and so do general patient guides for any under-the-skin injection125:

  • Belly: below the ribs and above the hip bones, at least 5 cm (2 inches) from the navel25.
  • Thigh: the front and outer side of the upper thigh25.
  • Back of the upper arm: at least 7.6 cm (3 inches) below the shoulder and 7.6 cm above the elbow5. The tirzepatide label says another person should give the injection here1.

People who inject insulin also use the upper outer buttock, and it carries the thickest fat of the four sites measured4. The GLP-1 labels don't list it, so your product's own instructions come first.

To see each site on a body, with the skin opened up to scale so you can see where the needle tip sits in the fat, open PepVault's free 3D Injection Guide at pepvault.app/lab/injection. It walks through the steps for a vial and syringe, a multi-dose pen or a single-dose pen.

Does the injection site change how much you absorb?

For the two most studied peptides, no. The semaglutide and tirzepatide labels state that similar exposure was achieved whether the injection went into the belly, thigh or upper arm1267. The semaglutide label adds that the injection site can be changed without any change to the dose2.

Where sites do differ is in how much liquid seeps back out. In human injection data, belly injections leaked less than thigh injections. In pig tissue, waiting at least 3 seconds before pulling the needle out leaked less than pulling it out straight away8.

We found no published site comparison for research peptides such as BPC-157, so the GLP-1 labels and the insulin research are the best guide available.

Why rotate injection sites?

Injecting the same patch again and again can build a rubbery, thickened area of fat called lipohypertrophy. In a study of 430 people who inject insulin, 64.4% had it. Among those who rotated sites correctly, only 5% did, and 98% of the people who had it either did not rotate or rotated incorrectly. Reusing needles more than five times raised the risk too9.

It matters because that tissue absorbs less evenly. When 13 people with type 1 diabetes injected insulin into lipohypertrophy instead of normal fat, absorption over the first four hours fell by about a fifth, and it became far less predictable from one injection to the next10. Expert injection guidance says not to inject into these areas, and that correct rotation helps prevent them11.

The tirzepatide label asks you to rotate within the area you choose, to lower the risk of pits, thickened skin or lumps at injection sites1. In practice:

  • Use a new spot every time, at least 2.5 cm (1 inch) from the last5.
  • You can stay in the same area, just not the same spot1.
  • One easy rhythm (a habit, not a label rule): split the belly into four quarters around the navel, keeping 5 cm clear of it, and move round them in one direction, one injection per quarter.
  • PepVault logs the site with each dose (left or right belly, thigh, back of the arm and more) and pre-selects the site in your rotation that you used longest ago.

Pinch or no pinch, and at what angle?

This depends on the needle, and the evidence comes from insulin, where the depth of skin and fat has been measured by ultrasound. Expert guidance names the shortest needles, the 4 mm pen needle and the 6 mm syringe needle, as the first choice for all patients: safe, effective and less painful11. Inserted at 90°, a 4 or 5 mm needle stays in the fat in virtually all adults4.

Longer needles are where the pinch earns its place. With an 8 mm needle inserted straight in without a pinch, the estimated chance of reaching muscle was 25% in the thigh and 9.7% in the belly, against 1.6% and 0.1% with a 4 mm needle. Going in at 45° lowers that chance with longer needles3. The thigh carries the least fat of the four sites, and the estimated risk of reaching muscle was highest there34.

  • 4 mm pen needle: straight in at 90°, which keeps the tip in the fat for nearly every adult4.
  • Insulin syringe: pinch about 2.5 cm (an inch) of skin and fat, not muscle, between your fingers and go in at 90°, or at 45° if there is not much fat5.
  • Single-dose pen: no pinch step; the base goes flat against the skin1.

Your product's instructions come first. The tirzepatide vial instructions, for example, say your healthcare provider should tell you whether to pinch the skin1.

Pen or syringe: what changes?

The sites are the same. What changes is how long the needle stays in. A single-dose tirzepatide pen is pressed and held for up to 10 seconds1. Semaglutide's multi-dose pen is held for a count of 6 seconds with the button pressed7. With a tirzepatide vial and syringe, the needle stays in the skin for at least 5 seconds1.

A drop of liquid or blood on the skin afterwards is normal: press a cotton ball or gauze on the spot and don't rub it1. Every needle is single-use. The tirzepatide label says to use a new syringe and needle for each injection1, and needle reuse was one of the risk factors for lipohypertrophy above9.

Which skin should you skip?

  • Skin that is tender, bruised, red, scaly or hard12.
  • Scars, stretch marks or damaged skin12.
  • Pits, thickened skin or lumps from earlier injections1.
  • The 5 cm (2 inches) around the navel2.

Start with clean, dry skin. Many instructions add an alcohol wipe; if you use one, let the skin dry before you inject25.

Is redness, a bump or a bruise normal?

Yes. Some soreness at the spot is expected5. In the weight-loss trials, injection-site reactions such as redness, itching, bruising or pain were reported in 6 to 8% of people on tirzepatide, against 2% on placebo1. On semaglutide for weight loss, reactions such as itching, redness or a firm spot were reported in 1.4%, against 1% on placebo2.

Simple care covers most of it: press, don't rub1, and give that spot a rest by choosing a fresh one next time15. A firm or thickened patch that stays is one to skip, and rotating helps keep new ones from forming19.

Redness that spreads, swelling, red streaks or a fever can be signs of an infection and are a reason to contact your clinician5.

What do people report?

Commonly reported: the belly is the easiest site to reach and the one most people settle on; the thigh stings a little more for some; a small pink or itchy patch that fades within a day or two is the most common complaint; and many BPC-157 users inject under the skin close to the sore tendon or joint.

These are user reports, not trial results. On the BPC-157 habit: a well-known rat study of a detached Achilles tendon gave the peptide by injection into the belly cavity, well away from the tendon, and still found better healing in strength, function and collagen12. We found no study that compares injecting near an injury with injecting elsewhere.

Track it in the app

Sources

  1. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection: prescribing information, patient information and instructions for use. DailyMed, revised 08/2026. dailymed.nlm.nih.gov
  2. Novo Nordisk. WEGOVY (semaglutide) injection: prescribing information, patient information and instructions for use. DailyMed, revised 06/2026. dailymed.nlm.nih.gov
  3. Hirsch L, Byron K, Gibney M. Intramuscular risk at insulin injection sites: measurement of the distance from skin to muscle and rationale for shorter-length needles for subcutaneous insulin therapy. Diabetes Technol Ther. 2014. PubMed 25329935
  4. Gibney MA, Arce CH, Byron KJ, Hirsch LJ. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Curr Med Res Opin. 2010. PubMed 20429833
  5. MedlinePlus (US National Library of Medicine). Subcutaneous (SQ) injections. Medical Encyclopedia. medlineplus.gov
  6. Eli Lilly and Company. MOUNJARO (tirzepatide) injection: prescribing information. DailyMed. dailymed.nlm.nih.gov
  7. Novo Nordisk. OZEMPIC (semaglutide) injection: prescribing information and instructions for use. DailyMed. dailymed.nlm.nih.gov
  8. Præstmark KA, Stallknecht B, Jensen ML et al. Injection technique and pen needle design affect leakage from skin after subcutaneous injections. J Diabetes Sci Technol. 2016. PubMed 26798083
  9. Blanco M, Hernández MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013. PubMed 23886784
  10. Famulla S, Hövelmann U, Fischer A et al. Insulin injection into lipohypertrophic tissue: blunted and more variable insulin absorption and action and impaired postprandial glucose control. Diabetes Care. 2016. PubMed 27411698
  11. Frid AH, Kreugel G, Grassi G et al. New insulin delivery recommendations (FITTER). Mayo Clin Proc. 2016. PubMed 27594187
  12. Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006. PubMed 16583442

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo